IOL Chemicals and Pharmaceuticals (IOLCP) Fundamentals 2026 — P/E 31.6x, Revenue Analysis | SniperIQ
IOL Chemicals and Pharmaceuticals (IOLCP) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹4,349 Crore, trading at ₹148.15 on the BSE. This SniperIQ fundamentals page covers IOL Chemicals and Pharmaceuticals's valuation (P/E 31.6x, P/B 2.4x), profitability (net margin 5.9%), revenue (₹2,319 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is IOL Chemicals and Pharmaceuticals's market cap?
IOL Chemicals and Pharmaceuticals (IOLCP) has a market capitalization of approximately ₹4,349 Crore, trading at ₹148.15 on the BSE. Market cap moves with the live share price.
What is IOL Chemicals and Pharmaceuticals's P/E ratio?
IOL Chemicals and Pharmaceuticals's trailing twelve-month P/E ratio is 31.6x, with a price-to-book (P/B) of 2.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is IOL Chemicals and Pharmaceuticals?
IOL Chemicals and Pharmaceuticals runs a net profit margin of 5.9%, a gross margin of 21.7%, and an operating margin of 8.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does IOL Chemicals and Pharmaceuticals generate?
IOL Chemicals and Pharmaceuticals reported revenue of ₹2,319 Crore for fiscal year 2026, with net income of ₹138 Crore and earnings per share (EPS) of 4.69. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does IOL Chemicals and Pharmaceuticals pay a dividend?
IOL Chemicals and Pharmaceuticals offers a trailing dividend yield of about 0.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is IOL Chemicals and Pharmaceuticals financially healthy?
IOL Chemicals and Pharmaceuticals carries a debt-to-equity ratio of 0.08x and a current ratio of 1.78x, with a market beta of 0.41. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is IOL Chemicals and Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For IOL Chemicals and Pharmaceuticals (IOLCP) the key facts are: market cap ₹4,349 Crore, P/E 31.6x, revenue ₹2,319 Crore, 52-week range 67.14-179.65. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track IOL Chemicals and Pharmaceuticals's full fundamentals live
Get IOL Chemicals and Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.